A carregar...
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC). pCR in this setting is associated with improved EFS. Whether NCT pr...
Na minha lista:
Publicado no: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Impact Journals LLC
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4914352/ https://ncbi.nlm.nih.gov/pubmed/26334099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.4801 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|